State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510182, China.
Central Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510180, China.
Virol Sin. 2021 Jun;36(3):373-381. doi: 10.1007/s12250-020-00307-1. Epub 2020 Nov 9.
Human adenoviruses (HAdVs) commonly cause many diseases such as respiratory diseases, gastroenteritis, cystitis worldwide. HAdV-3, -7, -4 and emergent HAdV-55 and HAdV-14 are the most important types causing severe respiratory diseases. There is no effective drug available for clinical treatment, and no vaccine available for the general population. Therefore, it is important to investigate the seroprevalence against HAdV for developing novel vaccines and vectors. In this study, we investigated the seroprevalence and titer levels of neutralizing antibodies (NAb) against HAdV-3, -4, -7, -14, -55, and -11 in total 278 healthy populations between 0 months and 49 years of age (228 children and 50 adults) from Guangzhou. In children under the age of 18 years, the seropositive rates were significantly increased against HAdV-3 at 12.07%, 33.96%, and 64.29% and against HAdV-7 at 0%, 18.87%, and 19.05% in age groups of 1-2, 3-5, and 6-17 years, respectively. The seroprevalence was very low (0% ~ 8.1%) for all other four types. In adults aged between 18 and 49 years, HAdV-3, -4, and -7 (> 50.00%) were the most common types, followed by HAdV-14 (38.00%), -55 (34.00%), and -11 (24.00%). Adults tended to have high NAb titers against HAdV-4 and -55. HAdV-55-seropositive donors tended to be HAdV-11- and HAdV-14-seropositive. These results indicated the low level of herd immunity against all six HAdV types in young children, and HAdV-14, -55, -11 in adults from Guangzhou City. Our findings demonstrate the importance of monitoring HAdV types and developing vaccines against HAdV for children and adults.
人腺病毒(HAdV)通常会在全球范围内引起多种疾病,如呼吸道疾病、胃肠炎、膀胱炎。HAdV-3、-7、-4 和新兴的 HAdV-55 和 HAdV-14 是引起严重呼吸道疾病的最重要类型。目前尚无有效的临床治疗药物,也没有针对普通人群的疫苗。因此,研究针对 HAdV 的血清流行率对于开发新型疫苗和载体非常重要。在这项研究中,我们调查了来自广州市 0 至 49 岁的 278 名健康人群(228 名儿童和 50 名成人)对 HAdV-3、-4、-7、-14、-55 和 -11 的血清阳性率和中和抗体(NAb)滴度水平。在 18 岁以下的儿童中,HAdV-3 在 1-2 岁、3-5 岁和 6-17 岁年龄组的血清阳性率分别显著增加至 12.07%、33.96%和 64.29%,HAdV-7 在 0%、18.87%和 19.05%。对于其他四种类型,血清阳性率非常低(0%~8.1%)。在 18 至 49 岁的成年人中,HAdV-3、-4 和 -7(>50.00%)是最常见的类型,其次是 HAdV-14(38.00%)、-55(34.00%)和 -11(24.00%)。成年人对 HAdV-4 和 -55 的 NAb 滴度较高。HAdV-55 血清阳性供体倾向于 HAdV-11 和 HAdV-14 血清阳性。这些结果表明,广州市幼童对所有六种 HAdV 类型的群体免疫力水平较低,而成人对 HAdV-14、-55、-11 的群体免疫力水平也较低。我们的研究结果表明,监测 HAdV 类型并为儿童和成人开发针对 HAdV 的疫苗非常重要。